The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to update their vaccines.

Key Takeaways Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine.The shot, Nuvaxovid, is designed for older adults and those between the ages of 12 and 64 who have underlying conditions that puts them at higher risk from the disease.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.